Evaluation of Xuefu Zhuyu Oral Solution as an Add-on Therapy for Stable Angina: Results from a Randomized Controlled Trial - Takeaways - MDSpire

Evaluation of Xuefu Zhuyu Oral Solution as an Add-on Therapy for Stable Angina: Results from a Randomized Controlled Trial

  • By

  • Wencong Cao

  • Shaojun Liao

  • Li Zhou

  • Geng Li

  • Junwen Jiang

  • Weihui Lv

  • Bo Dong

  • Li Liu

  • Jie Zhang

  • Yanchun Wang

  • Wenwei Ouyang

  • Yi Du

  • Zehuai Wen

  • April 29, 2026

  • 0 min

Share

  • 1

    Xuefu Zhuyu oral solution (XZOL) was evaluated as an adjunctive therapy for stable angina in a randomized controlled trial.

  • 2

    The trial included 148 patients who received either XZOL or placebo for 12 weeks, followed by a 12-week observation period.

  • 3

    Patients receiving XZOL experienced a significant reduction in angina pain intensity compared to the placebo group.

  • 4

    XZOL treatment also led to a lower requirement for rescue nitroglycerin at both 12 and 24 weeks.

  • 5

    The study concluded that XZOL is effective in reducing angina symptoms with a favorable safety profile.

Original Source(s)

Evaluation of Xuefu Zhuyu Oral Solution as an Add-on Therapy for Stable Angina: Results from a Randomized Controlled Trial

  • by Wencong Cao, Shaojun Liao, Li Zhou, Geng Li, Junwen Jiang, Weihui Lv, Bo Dong, Li Liu, Jie Zhang, Yanchun Wang, Wenwei Ouyang, Yi Du, Zehuai Wen

  • April 29, 2026

Related Content

Bereavement Tied to Higher Cardiovascular Risk

Acute post-loss period and pandemic conditions each amplified cardiovascular vulnerability in nationwide Swedish cohort study.

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Creation and assessment of a predictive model for the risk of myocardial hypoperfusion following primary PCI in patients with ST-segment elevation myocardial infarction